Pharming Group (PHAR) to Release Earnings on Thursday

Pharming Group (NASDAQ:PHAR) is expected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $111.7590 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 1:30 PM ET.

Pharming Group Stock Up 4.3%

PHAR opened at $16.67 on Wednesday. The firm has a market cap of $1.17 billion, a P/E ratio of -1,665.33 and a beta of 0.04. The business’s fifty day simple moving average is $17.35 and its 200 day simple moving average is $16.06. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Zacks Research cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Pharming Group presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Trading of Pharming Group

Hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC grew its stake in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Pharming Group in the 4th quarter worth approximately $360,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group during the fourth quarter valued at $224,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Pharming Group during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.